MedPath

Methylation of cfDNA in Diagnosing and Monitoring Pulmonary Nodule

Completed
Conditions
Pulmonary Nodule, Solitary
Interventions
Procedure: plasma cfDNA methylation
Registration Number
NCT03989219
Lead Sponsor
Jiayuan Sun
Brief Summary

Patients found pulmonary nodules by CT screening by will be enrolled in this study prospectively. Plasma cfDNA sequencing of these patients will be used to diagnose and monitor benign and malignant pulmonary nodules.

Detailed Description

This study prospectively included patients with pulmonary nodules (0.5-3 cm) diagnosed by CT. Methylation of plasma cfDNA in these patients will be performed. Evaluation of benign and malignant diagnostic efficacy of cfDNA methylation in pulmonary nodules with definite pathological findings. Pulmonary nodules that temporarily not require invasive examination will be performed CT follow-up and dynamically monitored methylation changes of cfDNA. And the methylation changes were to establish a model for the diagnosis and monitor of benign and malignant pulmonary nodules.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
401
Inclusion Criteria
    1. Inclusion criteria:

    2. Aged 40-80;

    3. Lung nodules were detected by CT (≥5mm,≤3cm);

    4. Patients fully understand the informed consent and can sign the informed consent in person.

Exclusion Criteria
    1. Exclusion criteria:

    2. Patients diagnosed with malignant tumors in the past;

    3. This image suggests pulmonary nodules with hilar or mediastinal lymph node enlargement;

    4. Pulmonary nodules are suspected of intrapulmonary metastasis of lung cancer or other malignancies;

    5. Past diseases or conditions that affect plasma cfDNA content, such as rheumatoid immunity and diseases of the blood system.

    6. The researchers concluded that there were other conditions that made it inappropriate to participate in this study

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
lung nodules were found by CT scanningplasma cfDNA methylationPlasma cfDNA will be performed in patients with pulmonary nodules (0.5-3 cm) found by CT scanning. Evaluation of benign and malignant diagnostic efficacy of cfDNA methylation in pulmonary nodules with clear pathological findings. Pulmonary nodules that could not or temporarily not require invasive examination will be performed CT follow-up and dynamically monitored methylation changes of cfDNA.
Primary Outcome Measures
NameTimeMethod
The efficacy of cfDNA methylation in the diagnosis of benign and malignant pulmonary nodules12 months

The sensitivity, specificity, positive predictive value, negative predictive value and accuracy are calculated according to standard definitions to evaluate the efficacy of cfDNA methylation in the diagnosis of benign and malignant pulmonary nodules .

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Shanghai Chest Hospital

🇨🇳

Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath